MYOD1 and cancer: Nevertheless, the majority of molecular alterations in pediatric cancers, including MYCN amplification and segmental chromosomal aberrations in neuroblastoma, and TP53, MYOD1 and RAS family gene mutations in soft-tissue sarcomas, provide no rationale for TT with available medications [1,22].